Indivior (LON:INDV) Stock Price Down 5%

Indivior PLC (LON:INDV - Get Free Report) fell 5% during trading on Monday . The company traded as low as GBX 768 ($9.96) and last traded at GBX 774 ($10.04). 1,059,445 shares changed hands during mid-day trading, an increase of 94% from the average session volume of 544,839 shares. The stock had previously closed at GBX 814.50 ($10.56).

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft lowered their price target on Indivior from GBX 2,350 ($30.48) to GBX 1,500 ($19.45) and set a "buy" rating for the company in a research report on Tuesday, July 9th.

Get Our Latest Analysis on Indivior

Indivior Trading Down 5.0 %

The firm has a 50 day simple moving average of GBX 1,273.11 and a 200 day simple moving average of GBX 1,409.72. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.93. The firm has a market cap of £1.05 billion, a P/E ratio of 25,800.00, a P/E/G ratio of -5.57 and a beta of 0.06.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Featured Stories

• Five stocks we like better than Indivior
• What is the NASDAQ Stock Exchange?
• Automaker's Bold Move to an EV Future: Is It Time to Buy Stock?
• 3 Tickers Leading a Meme Stock Revival
• Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
• How to Calculate Options Profits
• Major Gaming Stock to Watch: Why It's a Safe Bet Now

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ The attacks will come for me after releasing this… (From Porter & Company) (Ad)

Should you invest $1,000 in Indivior right now?

Before you consider Indivior, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.

While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here